3 QUESTIONS 1) Why would patients want a needle in the guts 2xweekly for 6 weeks when oral PPS is already on the market (Elmiron), 2) Did PAR's BME project magically become an OA trial, and 3) Buckley's chance of useful patent. All stoppers IMO.
Ann: PAR achieves 100 per cent recruitment in Phase 2b OA Trial, page-11
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $202.2K | 814.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 181098 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 118621 | 5 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |